Anti-CFD Therapeutic Antibody (Lampalizumab) (CAT#: TAB-754)

Recombinant humanized (from mouse) antibody Fab fragment expressed in CHO binding to human CFD. Lampalizumab is a humanized monoclonal antibody designed for the treatment of geographic atrophy secondary to age-related macular degeneration.

  • Published Data
  • Datasheet
  • MSDS
  • COA
Stim

Figure 1 Simulations of free target suppression in vitreous humor expressed as ratio of free target to baseline over time.

Solid black line represents the model-predicted vitreous humor free target ratio (FTR) for a typical patient in the CFD4870g study. Shaded region represents the 5th−95th prediction interval. Red, blue, and black lines denote the minimum FTR at 4, 6, and 8 weeks following intravitreal (ITV) lampalizumab administration. Black lines denote trend for a typical patient in CFD4870g study and shaded regions represent 5th−95th prediction intervals.

Le, K. N., Gibiansky, L., van Lookeren Campagne, M., Good, J., Davancaze, T., Loyet, K. M.,... & Jin, J. Y. (2015). Population pharmacokinetics and pharmacodynamics of lampalizumab administered intravitreally to patients with geographic atrophy. CPT: pharmacometrics & systems pharmacology, 4(10), 595-604.

ELISA

Figure 2 Systemic PK.

Systemic PK. (A) Simulated serum concentration time course of total lampalizumab (solid red line), free lampalizumab (dashed black line), total CFD (solid blue line), free CFD (solid green line), and the total lampalizumab-CFD complex (dotted magenta line) following ITV administration (1 and 10 mg/eye). (B) The lampalizumab fraction of the total dose that is cleared by linear clearance (red) and TMDD (blue) as a function of the ITV dose. The fractions of the drug eliminated by target-mediated clearance (TMCL) and linear clearance (CL) are defined as total drug elimination through binding to the CFD and through the first-order drug clearance mechanism, respectively, which is normalized by total drug elimination.

Govindan, S. V., Cardillo, T. M., Moon, S. J., Hansen, H. J., & Goldenberg, D. M. (2009). CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates. Clinical Cancer Research, 15(19), 6052-6061.


Specifications

  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Host Species
  • Mouse
  • Derivation
  • Humanized (from mouse)
  • Type
  • Fab - G1 - kappa
  • Species Reactivity
  • Human
  • Applications
  • ELISA, IP, FC, FuncS, Neut, IF, Stim
  • CAS
  • 1278466-20-8
  • Generic Name
  • lampalizumab
  • MW
  • 46.96 kDa
  • Related Disease
  • Age-related macular degeneration (AMD), neovascular (wet)

Applications

  • Application Notes
  • The CFD antibody has been reported in applications of ELISA, IP, FC, FuncS, Neut, IF, Stim.

Target

  • Alternative Names
  • lampalizumab;1278466-20-8;Anti-Factor D;RG7417;166-32;FCFD4514S;CFD;complement factor D (adipsin);D component of complement (adipsin) , DF, PFD, properdin factor D;complement factor D;ADN;properdin factor D;C3 convertase activator;complement factor D prep

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Resources

Please click here for more details about the introduction to mechanism of action, clinical projects and approved drugs of Lampalizumab

See other products for "CFD"

* Abbreviations
3D IHC3D Immunohistochemistry
ActivActivation
AgonistAgonist
ApopApoptosis
BABioassay
BIBioimaging
BlockBlocking
Cell ScreeningCell Screening
SeparationCell Separation
ChIPChromatin Immunoprecipitation
CMCDComplement Mediated Cell Depletion
CostimCostimulation
CytCytotoxicity
DepletionDepletion
DBDot Blot
EMElectron Microscopy
ELISAEnzyme-linked Immunosorbent Assay
ELISPOTEnzyme-linked Immunosorbent Spot
FCFlow Cytometry
FuncSFunctional Assay
GSGel Super Shift Assay
HAHemagglutination
IAImmunoassay
IBImmunoblotting
ICCImmunocytochemistry
IDImmunodiffusion
IFImmunofluorescence
IHCImmunohistochemistry
IHC-FrImmunohistochemistry-Frozen
IHC-PImmunohistochemistry-Paraffin
REImmunohistology - Resin Sections
IPImmunoprecipitation
IRMAImmunoradiometric Assay
SHIn situ hybridization
InhibInhibition
ICFCIntracellular Staining for Flow Cytometry
KO/KD-WBKnockout/Knockdown target confirmation by Western Blot
Live cell imagingLive cell imaging
CyTOF®Mass Cytometry
MeDIPMethylated DNA Immunoprecipitation
MultiplexMultiplex bead-based assay
NeutNeutralization
PPProtein Purification
PGProteogenomics
RIRadial Immunodiffusion
RIARadioimmunoassay
StimStimulation
SPRSurface Plasmon Resonance
TCTissue Culture
TBTurbidimetry
WBWestern Blot

Send Inquiry

  • Verification code
    Click image to refresh the verification code.
© 2007 - 2020 Creative BioLabs All Rights Reserved
  • 0
  • 0

Cart